Beth L. Abramson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beth L. Abramson has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Kajenny Srivaratharajah
Division of General Internal Medicine (Srivaratharajah), Department of Medicine, McMaster University, Hamilton, Ont.; Division of Cardiology (Abramson), Department of Medicine, University of Toronto, Toronto, Ont
2 shared publications- Alexander Michael Clark
Athabasca University
1 shared publication - Andrew M. Tershakovec
Merck & Co., Inc., Cardiovascular, Kenilworth, USA
1 shared publication - Arvind Kumar Shah
National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal
1 shared publication - Cheryl Pritlove
Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada
1 shared publication - Craig Dale
University of Toronto
1 shared publication
Latest Publications
- 10 February 2019
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 191 (6) , E159-E163
Identifying and managing younger women at high risk of cardiovascular disease
KEY POINTS Cardiovascular disease (CVD), which is largely preventable, is a leading cause of morbidity and mortality among Canadian women. For this article, we use CVD to refer to ischemic heart disease and stroke. Data for peripheral arterial disease in women are limited and are addressed elsewhere
- 10 February 2019
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 191 (6) , E159-E163
Identifying and managing younger women at high risk of cardiovascular disease
KEY POINTS Cardiovascular disease (CVD), which is largely preventable, is a leading cause of morbidity and mortality among Canadian women. For this article, we use CVD to refer to ischemic heart disease and stroke. Data for peripheral arterial disease in women are limited and are addressed elsewhere
- 1 April 2018
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 34 (4) , 356-361
Women and Peripheral Arterial Disease: A Review of Sex Differences in Epidemiology, Clinical Manifestations, and Outcomes
- 1 April 2018
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 34 (4) , 356-361
Women and Peripheral Arterial Disease: A Review of Sex Differences in Epidemiology, Clinical Manifestations, and Outcomes
- 1 March 2018
- Published by Elsevier in Social Science & Medicine
- Vol. 200, 44-51
Gender matters in cardiac rehabilitation and diabetes: Using Bourdieu's concepts
- 1 March 2018
- Published by Elsevier in Social Science & Medicine
- Vol. 200, 44-51
Gender matters in cardiac rehabilitation and diabetes: Using Bourdieu's concepts
- 1 May 2014
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 30 (5) , 553-559
Cardiovascular Risk in Women: Focus on Hypertension
- 1 May 2014
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 30 (5) , 553-559
Cardiovascular Risk in Women: Focus on Hypertension
- Open Access
- 1 January 2011
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 10 (1) , 146
Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients
Despite documented benefits of lipid-lowering treatment in women, a considerable number are undertreated, and fewer achieve treatment targets vs. men. Data were combined from 27 double-blind, active or placebo-controlled studies that randomized adult hypercholesterolemic patients to statin or statin+ezetimibe. Consistency of treatment effect among men (n = 11,295) and women (n = 10,499) was assessed and percent of men and women was calculated to evaluate the between-treatment ability to achieve specified treatment levels between sexes. Baseline lipids and hs-CRP were generally higher in women vs. men. Between-treatment differences were significant for both sexes (all p < 0.001 except apolipoprotein A-I in men = 0.0389). Men treated with ezetimibe+statin experienced significantly greater changes in LDL-C (p = 0.0066), non-HDL-C, total cholesterol, triglycerides, HDL-C, apolipoprotein A-I (all p < 0.0001) and apolipoprotein B (p = 0.0055) compared with women treated with ezetimibe+statin. The odds of achieving LDL-C < 100 mg/dL, apolipoprotein B < 90 mg/dL and the dual target [LDL-C < 100 mg/dL & apoliprotein B < 90 mg/dL] was significantly greater for women vs. men and the odds of achieving hs-CRP < 1 and < 2 mg/L and dual specified levels of [LDL-C < 100 mg/dL and hs-CRP < 2 mg/L] were significantly greater for men vs. women. Women reported significantly more gall-bladder-related, gastrointestinal-related, and allergic reaction or rash-related adverse events (AEs) vs. men (no differences between treatments). Men reported significantly more CK elevations (no differences between treatments) and hepatitis-related AEs vs. women (significantly more with ezetimibe+simvastatin vs. statin). These results suggest that small sex-related differences may exist in response to lipid-lowering treatment and achievement of specified lipid and hs-CRP levels, which may have implications when managing hypercholesterolemia in women.
- 1 January 2011
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 10 (1) , 146
Open AccessResponse by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients
Despite documented benefits of lipid-lowering treatment in women, a considerable number are undertreated, and fewer achieve treatment targets vs. men. Data were combined from 27 double-blind, active or placebo-controlled studies that randomized adult hypercholesterolemic patients to statin or statin+ezetimibe. Consistency of treatment effect among men (n = 11,295) and women (n = 10,499) was assessed and percent of men and women was calculated to evaluate the between-treatment ability to achieve specified treatment levels between sexes. Baseline lipids and hs-CRP were generally higher in women vs. men. Between-treatment differences were significant for both sexes (all p < 0.001 except apolipoprotein A-I in men = 0.0389). Men treated with ezetimibe+statin experienced significantly greater changes in LDL-C (p = 0.0066), non-HDL-C, total cholesterol, triglycerides, HDL-C, apolipoprotein A-I (all p < 0.0001) and apolipoprotein B (p = 0.0055) compared with women treated with ezetimibe+statin. The odds of achieving LDL-C < 100 mg/dL, apolipoprotein B < 90 mg/dL and the dual target [LDL-C < 100 mg/dL & apoliprotein B < 90 mg/dL] was significantly greater for women vs. men and the odds of achieving hs-CRP < 1 and < 2 mg/L and dual specified levels of [LDL-C < 100 mg/dL and hs-CRP < 2 mg/L] were significantly greater for men vs. women. Women reported significantly more gall-bladder-related, gastrointestinal-related, and allergic reaction or rash-related adverse events (AEs) vs. men (no differences between treatments). Men reported significantly more CK elevations (no differences between treatments) and hepatitis-related AEs vs. women (significantly more with ezetimibe+simvastatin vs. statin). These results suggest that small sex-related differences may exist in response to lipid-lowering treatment and achievement of specified lipid and hs-CRP levels, which may have implications when managing hypercholesterolemia in women.